{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:21:11Z","timestamp":1789608071458,"version":"build-2803163510"},"reference-count":147,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation (NRF) of Korea","doi-asserted-by":"publisher","award":["2021R1I1A3056261"],"award-info":[{"award-number":["2021R1I1A3056261"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation (NRF) of Korea","doi-asserted-by":"publisher","award":["K-MELLODDY"],"award-info":[{"award-number":["K-MELLODDY"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation (NRF) of Korea","doi-asserted-by":"publisher","award":["RS-2024-12345678"],"award-info":[{"award-number":["RS-2024-12345678"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"KRIBB Research Initiative Program","award":["2021R1I1A3056261"],"award-info":[{"award-number":["2021R1I1A3056261"]}]},{"name":"KRIBB Research Initiative Program","award":["K-MELLODDY"],"award-info":[{"award-number":["K-MELLODDY"]}]},{"name":"KRIBB Research Initiative Program","award":["RS-2024-12345678"],"award-info":[{"award-number":["RS-2024-12345678"]}]},{"name":"Korea Machine Learning Ledger Orchestration for Drug Discovery Project","award":["2021R1I1A3056261"],"award-info":[{"award-number":["2021R1I1A3056261"]}]},{"name":"Korea Machine Learning Ledger Orchestration for Drug Discovery Project","award":["K-MELLODDY"],"award-info":[{"award-number":["K-MELLODDY"]}]},{"name":"Korea Machine Learning Ledger Orchestration for Drug Discovery Project","award":["RS-2024-12345678"],"award-info":[{"award-number":["RS-2024-12345678"]}]},{"name":"Ministry of Health &amp; Welfare and the Ministry of Science and ICT, Republic of Korea","award":["2021R1I1A3056261"],"award-info":[{"award-number":["2021R1I1A3056261"]}]},{"name":"Ministry of Health &amp; Welfare and the Ministry of Science and ICT, Republic of Korea","award":["K-MELLODDY"],"award-info":[{"award-number":["K-MELLODDY"]}]},{"name":"Ministry of Health &amp; Welfare and the Ministry of Science and ICT, Republic of Korea","award":["RS-2024-12345678"],"award-info":[{"award-number":["RS-2024-12345678"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Inflammatory bowel disease (IBD) is a complex and chronic condition that requires the use of various pharmacological agents for its management. Despite advancements in IBD research, the multifaceted mechanisms involved continue to pose significant challenges for strategic prevention. Therefore, it is crucial to prioritize safe and effective treatment strategies using the currently available pharmacological agents. Given that patients with IBD often require multiple medications due to combination therapy or other underlying conditions, a comprehensive understanding of drug interactions is essential for optimizing treatment regimens. In this review, we examined the pharmacological treatment options recommended in the current IBD management guidelines and provided a comprehensive analysis of the known pharmacokinetic interactions associated with these medications. In particular, this review includes recent research results for the impact of anti-drug antibodies (ADAs) on the concentrations of biological agents used in IBD treatment. By leveraging detailed interaction data and employing personalized dosing strategies, healthcare providers can improve therapeutic outcomes and minimize adverse effects, ultimately improving the quality of care for patients with IBD.<\/jats:p>","DOI":"10.3390\/pharmaceutics16111431","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T03:52:07Z","timestamp":1731297127000},"page":"1431","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Drug Interaction-Informed Approaches to Inflammatory Bowel Disease Management"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2175-8876","authenticated-orcid":false,"given":"Kyeong-Ryoon","family":"Lee","sequence":"first","affiliation":[{"name":"Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju 28116, Republic of Korea"},{"name":"Department of Bioscience, University of Science and Technology, Daejeon 34113, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneela","family":"Gulnaz","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Woosuk University, Wanju 55338, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4921-4192","authenticated-orcid":false,"given":"Yoon-Jee","family":"Chae","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Woosuk University, Wanju 55338, Republic of Korea"},{"name":"Research Institute of Pharmaceutical Sciences, Woosuk University, Wanju 55338, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rodrigues, A.D. (2019). Drug-Drug Interactions, CRC Press.","DOI":"10.1201\/9780429131967"},{"key":"ref_2","first-page":"601","article-title":"Pharmacokinetic drug-drug interaction and their implication in clinical management","volume":"18","author":"Palleria","year":"2013","journal-title":"J. Res. Med. Sci. Off. J. Isfahan Univ. Med. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e065186","DOI":"10.1136\/bmjopen-2022-065186","article-title":"Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: A systematic analysis based on the Global Burden of Disease Study 2019","volume":"13","author":"Wang","year":"2023","journal-title":"BMJ Open"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Zhou, J.-L., Bao, J.-C., Liao, X.-Y., Chen, Y.-J., Wang, L.-W., Fan, Y.-Y., Xu, Q.-Y., Hao, L.-X., Li, K.-J., and Liang, M.-X. (2023). Trends and projections of inflammatory bowel disease at the global, regional and national levels, 1990\u20132050: A bayesian age-period-cohort modeling study. BMC Public Health, 23.","DOI":"10.1186\/s12889-023-17431-8"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/BF01312480","article-title":"Trends in incidence rates of ulcerative colitis and Crohn\u2019s disease","volume":"29","author":"Calkins","year":"1984","journal-title":"Dig. Dis. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/ng.3760","article-title":"Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease","volume":"49","author":"Moutsianas","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41586-020-2025-2","article-title":"Pathway paradigms revealed from the genetics of inflammatory bowel disease","volume":"578","author":"Graham","year":"2020","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host\u2013microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jgh.15222","article-title":"Systematic review and meta-analysis of the role of Faecalibacterium prausnitzii alteration in inflammatory bowel disease","volume":"36","author":"Zhao","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Zhou, Y., and Zhi, F. (2016). Lower level of bacteroides in the gut microbiota is associated with inflammatory bowel disease: A meta-analysis. BioMed Res. Int., 2016.","DOI":"10.1155\/2016\/5828959"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Baldelli, V., Scaldaferri, F., Putignani, L., and Del Chierico, F. (2021). The role of Enterobacteriaceae in gut microbiota dysbiosis in inflammatory bowel diseases. Microorganisms, 9.","DOI":"10.3390\/microorganisms9040697"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1389450118666170125144557","article-title":"Cytochrome P450 Structure, Function and Clinical Significance: A Review","volume":"19","author":"Manikandan","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Deodhar, M., Al Rihani, S.B., Arwood, M.J., Darakjian, L., Dow, P., Turgeon, J., and Michaud, V. (2020). Mechanisms of CYP450 inhibition: Understanding drug-drug interactions due to mechanism-based inhibition in clinical practice. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12090846"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41573-023-00877-1","article-title":"Membrane transporters in drug development and as determinants of precision medicine","volume":"23","author":"Galetin","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1124\/pr.113.007518","article-title":"Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects","volume":"65","author":"Fromm","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40005-022-00600-z","article-title":"A mechanism-based understanding of altered drug pharmacokinetics by gut microbiota","volume":"53","author":"Gulnaz","year":"2023","journal-title":"J. Pharm. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40005-021-00538-8","article-title":"Regulation of drug transporters by microRNA and implications in disease treatment","volume":"52","author":"Chae","year":"2022","journal-title":"J. Pharm. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5001\/omj.2011.21","article-title":"Food-drug interactions","volume":"26","author":"Bushra","year":"2011","journal-title":"Oman Med. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100880","DOI":"10.1016\/j.esmoop.2023.100880","article-title":"Drug\u2013drug interactions with proton pump inhibitors in cancer patients: An underrecognized cause of treatment failure","volume":"8","author":"Raoul","year":"2023","journal-title":"ESMO open"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1124\/dmd.111.039453","article-title":"Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences","volume":"39","author":"Wang","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4049\/jimmunol.1501780","article-title":"IgG1 allotypes influence the pharmacokinetics of therapeutic monoclonal antibodies through FcRn binding","volume":"196","author":"Ternant","year":"2016","journal-title":"J. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal Antibody Pharmacokinetics and Pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cei.12742","article-title":"From the bench to clinical practice: Understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals","volume":"184","author":"Gunn","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1298473","DOI":"10.1155\/2016\/1298473","article-title":"Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications","volume":"2016","author":"Kuriakose","year":"2016","journal-title":"J. Immunol. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/psp4.13073","article-title":"Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based pharmacokinetic modeling","volume":"13","author":"Chen","year":"2024","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/j.gastro.2018.12.009","article-title":"AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis","volume":"156","author":"Ko","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn\u2019s Disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/00365520310000591a","article-title":"Complementary Alternative Medicine in Patients with Inflammatory Bowel Disease: Use and Attitudes","volume":"38","author":"Quattropani","year":"2003","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Karthikeyan, A., Young, K.N., Moniruzzaman, M., Beyene, A.M., Do, K., Kalaiselvi, S., and Min, T. (2021). Curcumin and Its Modified Formulations on Inflammatory Bowel Disease (IBD): The Story So Far and Future Outlook. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13040484"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s10787-021-00856-1","article-title":"A review of the biological and pharmacological activities of mesalazine or 5-aminosalicylic acid (5-ASA): An anti-ulcer and anti-oxidant drug","volume":"29","author":"Beiranvand","year":"2021","journal-title":"Inflammopharmacology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0009-9236(99)80117-9","article-title":"Inhibition of nuclear factor kappa B (NF-kB) by aminosalicylates: Structure activity relationships","volume":"65","author":"Egan","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1179\/135100010X12826446921707","article-title":"Scavenging of reactive oxygen and nitrogen species by the prodrug sulfasalazine and its metabolites 5-aminosalicylic acid and sulfapyridine","volume":"15","author":"Couto","year":"2010","journal-title":"Redox Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1084\/jem.20041948","article-title":"Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator\u2013activated receptor-\u03b3","volume":"201","author":"Rousseaux","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.0954-6820.1942.tb06841.x","article-title":"Salazopyrin, a new sulfanilamide preparation. A. Therapeutic Results in Rheumatic Polyarthritis. B. Therapeutic Results in Ulcerative Colitis. C. Toxic Manifestations in Treatment with Sulfanilamide Preparations","volume":"110","author":"Svartz","year":"1942","journal-title":"Acta Medica Scand."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2165\/00003088-197601060-00002","article-title":"Clinical pharmacokinetics of sulphasalazine","volume":"1","author":"Das","year":"1976","journal-title":"Clin. Pharmacokinet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00003495-199550010-00009","article-title":"Sulfasalazine: A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis","volume":"50","author":"Rains","year":"1995","journal-title":"Drugs"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/14712598.2019.1666101","article-title":"Modern use of 5-aminosalicylic acid compounds for ulcerative colitis","volume":"20","author":"Roda","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/00365528809101539","article-title":"Pharmacology of olsalazine","volume":"23","author":"Campbell","year":"1988","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1021\/mp050113v","article-title":"Breast cancer resistance protein (Bcrp\/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse","volume":"3","author":"Zaher","year":"2006","journal-title":"Mol. Pharm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1124\/dmd.117.078931","article-title":"Curcumin as an in vivo selective intestinal breast cancer resistance protein inhibitor in cynomolgus monkeys","volume":"46","author":"Karibe","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1476-5381.2012.01887.x","article-title":"Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP","volume":"166","author":"Kusuhara","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Song, Y.K., Yoon, J.H., Woo, J.K., Kang, J.H., Lee, K.R., Oh, S.H., Chung, S.J., and Maeng, H.J. (2020). Quercetin is a flavonoid breast cancer resistance protein inhibitor with an impact on the oral pharmacokinetics of sulfasalazine in rats. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12050397"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Oh, J.H., Kim, D., Lee, H., Kim, G., Park, T., Kim, M.C., and Lee, Y.J. (2021). Negligible effect of quercetin in the pharmacokinetics of sulfasalazine in rats and beagles: Metabolic inactivation of the interaction potential of quercetin with bcrp. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13121989"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"G371","DOI":"10.1152\/ajpgi.00102.2009","article-title":"Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting","volume":"297","author":"Dahan","year":"2009","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/jcph.1005","article-title":"Effects of rolapitant administered intravenously or orally on the pharmacokinetics of digoxin (P-glycoprotein substrate) and sulfasalazine (breast cancer resistance","volume":"58","author":"Wang","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Dahan, A., and Pharmaceutics, G.A.-I.J. (2010). MRP2 Mediated Drug\u2013Drug Interaction: Indomethacin Increases Sulfasalazine Absorption in the Small Intestine, Potentially Decreasing Its Colonic Targeting, Elsevier.","DOI":"10.1016\/j.ijpharm.2009.11.021"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"486","DOI":"10.4062\/biomolther.2015.041","article-title":"Measurement of human cytochrome P450 enzyme induction based on mesalazine and mosapride citrate treatments using a luminescent assay","volume":"23","author":"Kim","year":"2015","journal-title":"Biomol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1124\/dmd.110.034991","article-title":"Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake","volume":"39","author":"Glaeser","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Bruscoli, S., Febo, M., Riccardi, C., and Migliorati, G. (2021). Glucocorticoid therapy in inflammatory bowel disease: Mechanisms and clinical practice. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.691480"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4645","DOI":"10.1210\/jc.2009-1412","article-title":"11\u03b2-Hydroxysteroid Dehydrogenase Type 1 and Its Role in the Hypothalamus-Pituitary-Adrenal Axis, Metabolic Syndrome, and Inflammation","volume":"94","author":"Cooper","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-197904020-00004","article-title":"Clinical pharmacokinetics of prednisone and prednisolone","volume":"4","author":"Pickup","year":"1979","journal-title":"Clin. Pharmacokinet."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/jphp.12820","article-title":"Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat","volume":"69","author":"Hossain","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/01.qai.0000187444.38461.70","article-title":"Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers","volume":"40","author":"Penzak","year":"2005","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1034\/j.1399-3046.1999.00027.x","article-title":"Diltiazem retards the metabolism of oral prednisone with effects on T-cell markers","volume":"3","author":"Diltiazem","year":"1999","journal-title":"Pediatr. Transplant."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/jcph.338","article-title":"Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs\u2013midazolam and odanacatib","volume":"54","author":"Marcantonio","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1365-2125.2001.01372.x","article-title":"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects","volume":"51","author":"Diquet","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1600-0773.1999.tb01059.x","article-title":"Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers","volume":"85","author":"Varis","year":"1999","journal-title":"Pharmacol. Toxicol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0009-9236(98)90066-2","article-title":"Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole","volume":"64","author":"Varis","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s002280000171","article-title":"Grapefruit juice can increase the plasma concentrations of oral methylprednisolone","volume":"56","author":"Varis","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1067\/mcp.2002.127944","article-title":"Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers","volume":"72","author":"Booker","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0009-9236(03)00066-3","article-title":"Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone","volume":"74","author":"McCrea","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/01.jcp.0000095343.32154.1d","article-title":"Nefazodone Inhibits Methylprednisolone Disposition and Enhances its Adrenal-Suppressant Effect","volume":"23","author":"Kotlyar","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1067\/mcp.2000.106895","article-title":"Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration","volume":"68","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_69","first-page":"461","article-title":"Grapefruit juice interaction with oral budesonide: Equal effect on immediate-release and delayed-release formulations","volume":"64","author":"Randvall","year":"2009","journal-title":"Pharmazie"},{"key":"ref_70","first-page":"1047","article-title":"Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes","volume":"41","author":"Pichard","year":"1992","journal-title":"Mol. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00296-017-3653-1","article-title":"Polymorphisms in the multidrug-resistance 1 gene related to glucocorticoid response in rheumatoid arthritis treatment","volume":"37","author":"Cuppen","year":"2017","journal-title":"Rheumatol. Int."},{"key":"ref_72","first-page":"137","article-title":"Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver","volume":"23","author":"Jonsson","year":"1995","journal-title":"Drug Metab. Dispos."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1080\/00498254.2017.1344911","article-title":"In vitro drug\u2013drug interactions of budesonide: Inhibition and induction of transporters and cytochrome P450 enzymes","volume":"48","author":"Chen","year":"2018","journal-title":"Xenobiotica"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1478-3231.2005.01222.x","article-title":"Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis","volume":"26","author":"Dilger","year":"2006","journal-title":"Liver Int."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5217\/ir.2020.00155","article-title":"Use of thiopurines in inflammatory bowel disease: An update","volume":"20","author":"Singh","year":"2022","journal-title":"Intest. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/j.1572-0241.2008.01848.x","article-title":"Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: A review","volume":"103","author":"Gisbert","year":"2008","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.1365-2362.2010.02346.x","article-title":"Thiopurine metabolism monitoring: Implications in inflammatory bowel diseases","volume":"40","author":"Dewit","year":"2010","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1432-2277.2005.00095.x","article-title":"Severe azathioprine-induced myelotoxicity in a kidney transplant patient with thiopurine S-methyltransferase-deficient genotype (TPMT*3A\/*3C)","volume":"18","author":"Kurzawski","year":"2005","journal-title":"Transpl. Int."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update","volume":"105","author":"Relling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1124\/dmd.107.016287","article-title":"Inhibition of Human Thiopurine S-Methyltransferase (TPMT) by Various NSAIDs in vitro: A Mechanism for Possible Drug Interactions","volume":"35","author":"Oselin","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.14309\/00000434-200410001-00810","article-title":"A double-blind, placebo-controlled randomized clinical trial evaluating the effects of sulfasalazine on 6-mercaptopurine metabolism in patients with crohn\u2019s disease","volume":"99","author":"Achkar","year":"2004","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/01.MIB.0000206544.05661.9f","article-title":"5-Aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine","volume":"12","author":"Hande","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_83","first-page":"637","article-title":"Concomitant 5-aminosalicylic acid treatment does not affect 6-thioguanine nucleotide levels in patients with inflammatory bowel disease on thiopurines","volume":"36","author":"Looser","year":"2023","journal-title":"Ann. Gastroenterol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0009-9236(97)90125-9","article-title":"Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction","volume":"62","author":"Lewis","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/gut.49.5.656","article-title":"Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide","volume":"49","author":"Lowry","year":"2001","journal-title":"Gut"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/clpt.1983.254","article-title":"Inhibition of first-pass metabolism in cancer chemotherapy: Interaction of 6-mercaptopurine and allopurinol","volume":"34","author":"Zimm","year":"1983","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2036.2005.02583.x","article-title":"Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine","volume":"22","author":"Sparrow","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1111\/bcp.14625","article-title":"Influence of allopurinol on thiopurine associated toxicity: A retrospective population-based cohort study","volume":"87","author":"Houwen","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/apt.14571","article-title":"Randomised clinical trial: Efficacy, safety and dosage of adjunctive allopurinol in azathioprine\/mercaptopurine nonresponders (AAA Study)","volume":"47","author":"Friedman","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"101332","DOI":"10.1016\/j.eclinm.2022.101332","article-title":"Low-dose azathioprine and allopurinol versus azathioprine monotherapy in patients with ulcerative colitis (AAUC): An investigator-initiated, open, multicenter, parallel-arm, randomised controlled trial","volume":"45","author":"Theede","year":"2022","journal-title":"eClinicalMedicine"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/clpt.1987.45","article-title":"The effect of methotrexate on the bioavailability of oral 6-mercaptopurine","volume":"41","author":"Balis","year":"1987","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/humu.20694","article-title":"6-Mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4","volume":"29","author":"Janke","year":"2008","journal-title":"Hum. Mutat."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"El-Sheikh, A., Greupink, R., Wortelboer, H.M., Van Den Heuvel, J.J., Schreurs, M., Koenderink, J.B., Masereeuw, R., and Russel, F.G. (2013). Interaction of Immunosuppressive Drugs with Human Organic Anion Transporter (OAT) 1 and OAT3, and Multidrug Resistance-Associated Protein (MRP) 2 and MRP4, Elsevier.","DOI":"10.1016\/j.trsl.2013.08.003"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/IJN.S394819","article-title":"Cellular Uptake and Transport Mechanism of 6-Mercaptopurine Nanomedicines for Enhanced Oral Bioavailability","volume":"18","author":"Zou","year":"2023","journal-title":"Int. J. Nanomed."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1158\/0008-5472.CAN-07-6790","article-title":"Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity","volume":"68","author":"Krishnamurthy","year":"2008","journal-title":"Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00535-010-0248-y","article-title":"The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease","volume":"45","author":"Ban","year":"2010","journal-title":"J. Gastroenterol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"688","DOI":"10.25259\/IJDVL_8_2023","article-title":"JAK inhibitor: Introduction","volume":"89","author":"Raychaudhuri","year":"2023","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2147\/DDDT.S436549","article-title":"The Impact of Baohuoside I on the Metabolism of Tofacitinib in Rats","volume":"18","author":"Shi","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Wang, Y., Zhou, Q., Wang, H., Song, W., Wang, J., Mamun, A.A., Geng, P., Zhou, Y., and Wang, S. (2024). Effect of P. corylifolia on the pharmacokinetic profile of tofacitinib and the underlying mechanism. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1351882"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/cpdd.71","article-title":"Evaluation of the effect of fluconazole and ketoconazole on the pharmacokinetics of tofacitinib in healthy adult subjects","volume":"3","author":"Gupta","year":"2013","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Ye, Z., Xia, H., Hu, J., Liu, Y., Wang, A., Cai, J., Hu, G., and Xu, R. (2024). CYP3A4 and CYP2C19 genetic polymorphisms and myricetin interaction on tofacitinib metabolism. Biomed. Pharmacother., 175.","DOI":"10.1016\/j.biopha.2024.116421"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/13880209.2020.1738504","article-title":"Effects of naringenin on the pharmacokinetics of tofacitinib in rats","volume":"58","author":"Wang","year":"2020","journal-title":"Pharm. Biol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Ye, Z., Hu, J., Wang, J., Liu, Y.-N., Hu, G.-X., and Xu, R.-A. (2023). The effect of Resveratrol on the pharmacokinetic profile of tofacitinib and the underlying mechanism. Chem.-Biol. Interact., 374.","DOI":"10.1016\/j.cbi.2023.110398"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Lee, J.-S., Kim, H.-S., Jung, Y.-S., Choi, H.-G., and Kim, S.-H. (2021). Pharmacokinetic drug interaction between tofacitinib and voriconazole in rats. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13050740"},{"key":"ref_105","unstructured":"Tofacitinib (2024, August 13). Clinical Pharmacology and Biopharmaceutics Review. United States Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203214Orig1s000ClinPharmR.pdf."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/cpdd.270","article-title":"Evaluation of the effect of tofacitinib on the pharmacokinetics of oral contraceptive steroids in healthy female volunteers","volume":"5","author":"Menon","year":"2016","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2125.2012.04168.x","article-title":"Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: Confirmation of in vitro data","volume":"74","author":"Gupta","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1124\/dmd.113.054940","article-title":"The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans","volume":"42","author":"Dowty","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1111\/bcp.13329","article-title":"Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib","volume":"83","author":"Mohamed","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_110","unstructured":"Upadacitinib (2024, August 13). Clinical Pharmacology and Biopharmaceutics Review. United States Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211675Orig1s000ClinPharmR.pdf."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/cpdd.844","article-title":"Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate","volume":"10","author":"Mohamed","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/flgastro-2018-101057","article-title":"Antibiotics and probiotics in inflammatory bowel disease: When to use them?","volume":"11","author":"Abraham","year":"2020","journal-title":"Frontline Gastroenterol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2165\/00003088-199019060-00003","article-title":"Clinical Pharmacokinetics of Ciprofloxacin","volume":"19","author":"Guay","year":"1990","journal-title":"Clin. Pharmacokinet."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/j.1745-7254.2008.00908.x","article-title":"Determination of the inhibitory potential of 6 fuoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes","volume":"29","author":"Zhang","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1742-7843.2008.00252.x","article-title":"In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: Predictability of in vivo interactions","volume":"103","author":"Karjalainen","year":"2008","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.clpt.2004.08.018","article-title":"Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism","volume":"76","author":"Granfors","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s002280000192","article-title":"Ciprofloxacin increases serum clozapine and N-desmethylclozapine: A study in patients with schizophrenia","volume":"56","author":"Raaska","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejps.2018.01.002","article-title":"The inhibitory effects of eighteen front-line antibiotics on the substrate uptake mediated by human Organic anion\/cation transporters, Organic anion transporting polypeptides and Oligopeptide transporters in in vitro models","volume":"115","author":"Lu","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1128\/AAC.01151-16","article-title":"Inhibitory interaction potential of 22 antituberculosis drugs on organic anion and cation transporters of the SLC22A family","volume":"60","author":"Kaisar","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/bdd.488","article-title":"The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers","volume":"27","author":"Hedaya","year":"2006","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Zemanov\u00e1, N., Ln\u011bni\u010dkov\u00e1, K., Vavre\u010dkov\u00e1, M., Anzenbacherov\u00e1, E., Anzenbacher, P., Zapletalov\u00e1, I., Hermanov\u00e1, P., Hudcovic, T., Koz\u00e1kov\u00e1, H., and Jourov\u00e1, L. (2021). Gut microbiome affects the metabolism of metronidazole in mice through regulation of hepatic cytochromes P450 expression. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0259643"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s002280000201","article-title":"Effects of metronidazole on midazolam metabolism in vitro and in vivo","volume":"56","author":"Wang","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1345\/aph.1H401","article-title":"Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered?","volume":"41","author":"Roedler","year":"2007","journal-title":"Ann. Pharmacother."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/flgastro-2018-101054","article-title":"Recent advances in monoclonal antibody therapy in IBD: Practical issues","volume":"10","author":"Tamilarasan","year":"2019","journal-title":"Frontline Gastroenterol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/gut.40.4.443","article-title":"Tumour necrosis factor and Crohn\u2019s disease","volume":"40","year":"1997","journal-title":"Gut"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40262-017-0627-0","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease","volume":"57","author":"Hemperly","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/FTD.0b013e318180e300","article-title":"Infliximab pharmacokinetics in inflammatory bowel disease patients","volume":"30","author":"Ternant","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.dld.2019.05.001","article-title":"Positive pharmacokinetic effect of azathioprine co-medication on infliximab trough levels is dose-dependent","volume":"51","author":"Polakovicova","year":"2019","journal-title":"Dig. Liver Dis."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e001047","DOI":"10.1136\/rmdopen-2019-001047","article-title":"Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: A multicentric randomised trial","volume":"6","author":"Ducourau","year":"2020","journal-title":"RMD open"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/annrheumdis-2013-204769","article-title":"Efficacy and safety of ascending methotrexate dose in combination with adalimumab: The randomised CONCERTO trial","volume":"74","author":"Burmester","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11095-019-2696-2","article-title":"Methotrexate Reduces the Clearance of Adalimumab by Increasing the Concentration of Neonatal Fc Receptor in Tissues","volume":"36","author":"Deng","year":"2019","journal-title":"Pharm. Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e001149","DOI":"10.1136\/bmjgast-2023-001149","article-title":"Association between 6-thioguanine nucleotide levels and preventing production of antibodies to infliximab in patients with inflammatory bowel disease","volume":"10","author":"Phillips","year":"2023","journal-title":"BMJ open Gastroenterol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2013.11.024","article-title":"Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn\u2019s Disease","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.gastro.2023.03.224","article-title":"Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn\u2019s Disease: A Pragmatic Randomized Trial","volume":"165","author":"Kappelman","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1177\/0091270009339192","article-title":"Population Pharmacokinetics of Golimumab, an Anti-Tumor Necrosis Factor-\u03b1 Human Monoclonal Antibody, in Patients With Psoriatic Arthritis","volume":"49","author":"Xu","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Zhuang, Y., Xu, Z., Frederick, B., de Vries, D.E., Ford, J.A., Keen, M., Doyle, M.K., Petty, K.J., Davis, H.M., and Zhou, H. (2012). Golimumab Pharmacokinetics After Repeated Subcutaneous and Intravenous Administrations in Patients with Rheumatoid Arthritis and the Effect of Concomitant, Elsevier.","DOI":"10.1016\/j.clinthera.2011.11.015"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1208\/s12248-018-0219-4","article-title":"Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNF\u03b1 Monoclonal Antibody","volume":"20","author":"Wang","year":"2018","journal-title":"AAPS J."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/apt.13243","article-title":"Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn\u2019s disease","volume":"42","author":"Rosario","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/cpdd.891","article-title":"Assessment of vedolizumab disease-drug-drug interaction potential in patients with inflammatory bowel diseases","volume":"10","author":"Sun","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1080\/14712598.2020.1792882","article-title":"Ustekinumab for treating ulcerative colitis: An expert opinion","volume":"20","author":"Biancone","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ecco-jcc\/jjz110","article-title":"IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn\u2019s Disease","volume":"14","author":"Hanauer","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_146","unstructured":"Ustekinuamb (2024, August 13). Clinical Pharmacology and Biopharmaceutics Review. United States Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/761044Orig1s000ClinPharmR.pdf."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1053\/j.gastro.2018.01.043","article-title":"Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn\u2019s Disease","volume":"154","author":"Adedokun","year":"2018","journal-title":"Gastroenterology"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/11\/1431\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:29:49Z","timestamp":1760113789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/11\/1431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,10]]},"references-count":147,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["pharmaceutics16111431"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16111431","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,10]]}}}